Next Article in Journal
MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
Previous Article in Journal
Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
Open AccessCase Report

Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still’s Disease—Denosumab Efficacy in Osteoporotic Still’s Disease Patients

1
Department of Orthopaedic Surgery, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, Japan
2
Department of Orthopaedic Surgery, Showa Inan General Hospital, Akaho 3230, Komagane 399-4117, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(4), 63; https://doi.org/10.3390/jcm7040063
Received: 8 January 2018 / Revised: 7 March 2018 / Accepted: 20 March 2018 / Published: 22 March 2018
(This article belongs to the Section Pharmacology)
Adult-onset Still’s disease (AOSD) is an autoimmune inflammatory disorder. Glucocorticoids are often used for AOSD, which may induce complicating glucocorticoid-induced osteoporosis (GIO). An anti-resorption drug, denosumab, has recently been approved for osteoporosis treatment in Japan. However, the drug’s efficacy for GIO in AOSD is largely unknown. This retrospective, consecutive case series investigated two patients with GIO in AOSD to examine the effects of denosumab on bone metabolism. Bone turnover markers, and bone mineral density (BMD) of the lumbar 1–4 spine (L-BMD) and bilateral total hips (H-BMD) were followed for six months in a male patient and for twelve months in a female patient. No fractures or severe side effects, such as hypocalcemia, were observed during the observational period. Bone turnover markers were basically suppressed, and L-BMD and H-BMD were increased by denosumab in both patients. Our findings suggest that denosumab is a suitable candidate drug for GIO in AOSD. View Full-Text
Keywords: adult-onset Still’s disease; bone mineral density; denosumab; osteoporosis adult-onset Still’s disease; bone mineral density; denosumab; osteoporosis
Show Figures

Figure 1

MDPI and ACS Style

Kumaki, D.; Nakamura, Y.; Suzuki, T.; Kato, H. Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still’s Disease—Denosumab Efficacy in Osteoporotic Still’s Disease Patients. J. Clin. Med. 2018, 7, 63.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop